Summit Securities Group LLC Invests $38,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,560 shares of the company’s stock, valued at approximately $38,000.

Several other large investors have also recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership raised its stake in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd bought a new position in Hims & Hers Health in the 4th quarter worth about $41,104,000. Principal Financial Group Inc. grew its position in Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock valued at $33,024,000 after purchasing an additional 1,075,355 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 8.8 %

NYSE HIMS opened at $29.11 on Monday. The company has a 50-day moving average price of $39.88 and a 200-day moving average price of $29.58. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm has a market capitalization of $6.47 billion, a P/E ratio of 66.15 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 36,460 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $27.09, for a total value of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $756,298.62. This represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,061,718 shares of company stock worth $37,894,395 over the last quarter. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Truist Financial upped their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Piper Sandler upped their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Finally, Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.